business

Pfizer buying spree continues with $5.4 bil hematology deal

1 Comment
By TOM MURPHY and MICHELLE CHAPMAN

The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.

© Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

©2022 GPlusMedia Inc.

1 Comment
Login to comment

Pfizer Inc.'s top-selling COVID-19 vaccine and treatment have left the New York City drugmaker flush with cash to spend on an acquisition feel. The vaccine and treatment brought in more than $16 billion combined just in the recently completed second quarter.

When there's a crisis there's an opportunity

1 ( +1 / -0 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites